{"id":4060,"date":"2018-05-16T21:47:33","date_gmt":"2018-05-16T21:47:33","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=4060"},"modified":"2020-12-13T18:14:09","modified_gmt":"2020-12-13T23:14:09","slug":"eiger-press-release-2","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/bn\/2018\/05\/16\/eiger-press-release-2\/","title":{"rendered":"JAMA \u09b8\u09cd\u099f\u09be\u09a1\u09bf\u09b0 \u09b9\u09bf\u09b2\u0997\u09c1\u09b2\u09bf\u09a4\u09c7, \u09b2\u09cb\u09a8\u09be\u09ab\u09be\u09b0\u09a8\u09bf\u09ac\u09c7\u09b0 \u098f\u09ab\u09a1\u09bf\u098f \u0985\u09a8\u09c1\u09ae\u09cb\u09a6\u09a8\u09c7\u09b0 \u099c\u09a8\u09cd\u09af \u09aa\u09bf\u0986\u09b0\u098f\u09ab \u098f\u09ac\u0982 \u0986\u0987\u0997\u09be\u09b0 \u09ac\u09be\u09af\u09bc\u09cb\u09ab\u09be\u09b0\u09cd\u09ae\u09be\u09b8\u09bf\u0989\u099f\u09bf\u0995\u09cd\u09af\u09be\u09b2\u09b8 \u0985\u0982\u09b6\u09c0\u09a6\u09be\u09b0"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22&#8243;][et_pb_row _builder_version=&#8221;3.25&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.6.5&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>Collaboration marks the first submission for the treatment of Progeria. If approved, children may access drug by prescription instead of clinical trial!!<\/p>\n<p>Read our latest press releases here:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria<\/a><\/li>\n<\/ul>\n<div id=\"attachment_9151\" style=\"width: 285px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-9151\" class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/><p id=\"caption-attachment-9151\" class=\"wp-caption-text\">Zoey and Carly getting their lonafarnib treatment during their latest clinical trial visit to Boston.<\/p><\/div>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>JAMA \u09b8\u09cd\u099f\u09be\u09a1\u09bf\u09b0 \u09b9\u09bf\u09b2, \u09b2\u09cb\u09a8\u09be\u09ab\u09be\u09b0\u09a8\u09bf\u09ac\u09c7\u09b0 \u098f\u09ab\u09a1\u09bf\u098f \u0985\u09a8\u09c1\u09ae\u09cb\u09a6\u09a8\u09c7\u09b0 \u099c\u09a8\u09cd\u09af \u09aa\u09bf\u0986\u09b0\u098f\u09ab \u098f\u09ac\u0982 \u0986\u0987\u0997\u09be\u09b0 \u09ac\u09be\u09af\u09bc\u09cb\u09ab\u09be\u09b0\u09cd\u09ae\u09be\u09b8\u09bf\u0989\u099f\u09bf\u0995\u09cd\u09af\u09be\u09b2\u09b8 \u0985\u0982\u09b6\u09c0\u09a6\u09be\u09b0\u0964 \t<\/p>","protected":false},"author":2,"featured_media":11817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p>Collaboration marks the first submission for the treatment of Progeria. If approved, children may access drug by prescription instead of clinical trial!!<\/p><p>Read our latest press releases here:<\/p><ul><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals\u00a0<\/a><\/li><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria<\/a><\/li><\/ul>[caption id=\"attachment_9151\" align=\"aligncenter\" width=\"275\"]<img class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/> Zoey and Carly getting their lonafarnib treatment during their latest clinical trial visit to Boston.[\/caption]<p>\u00a0<\/p>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-4060","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-news","post_format-post-format-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/bn\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/bn\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-16T21:47:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-13T23:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u09ae\u09bf\u09a8\u09bf\u099f\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"bn-BD\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/\",\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#breadcrumb\"},\"inLanguage\":\"bn-BD\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"bn-BD\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"width\":300,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/nl\\\/2018\\\/05\\\/16\\\/eiger-press-release-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.progeriaresearch.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"bn-BD\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"bn-BD\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ProgeriaResearch\\\/\",\"https:\\\/\\\/x.com\\\/Progeria\",\"https:\\\/\\\/www.instagram.com\\\/progeriaresearch\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"bn-BD\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/bn\\\/author\\\/karenb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/bn\/2018\/05\/16\/eiger-press-release-2\/","og_locale":"en_US","og_type":"article","og_title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","og_description":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.","og_url":"https:\/\/www.progeriaresearch.org\/bn\/2018\/05\/16\/eiger-press-release-2\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2018-05-16T21:47:33+00:00","article_modified_time":"2020-12-13T23:14:09+00:00","og_image":[{"width":300,"height":225,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 \u09ae\u09bf\u09a8\u09bf\u099f"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","articleSection":["News"],"inLanguage":"bn-BD","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","url":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb"},"inLanguage":"bn-BD","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"]}]},{"@type":"ImageObject","inLanguage":"bn-BD","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","width":300,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u09aa\u09cd\u09b0\u09cb\u099c\u09c7\u09b0\u09bf\u09af\u09bc\u09be \u09b0\u09bf\u09b8\u09be\u09b0\u09cd\u099a \u09ab\u09be\u0989\u09a8\u09cd\u09a1\u09c7\u09b6\u09a8","description":"\u09b6\u09bf\u09b6\u09c1\u09a6\u09c7\u09b0 \u099c\u09a8\u09cd\u09af \u2665 \u09a8\u09bf\u09b0\u09be\u09ae\u09af\u09bc\u09c7\u09b0 \u099c\u09a8\u09cd\u09af","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"bn-BD"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u09aa\u09cd\u09b0\u09cb\u099c\u09c7\u09b0\u09bf\u09af\u09bc\u09be \u09b0\u09bf\u09b8\u09be\u09b0\u09cd\u099a \u09ab\u09be\u0989\u09a8\u09cd\u09a1\u09c7\u09b6\u09a8","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"bn-BD","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u0995\u09be\u09b0\u09c7\u09a8 \u09ac\u09c7\u099f\u09c1\u09b0\u09cd\u09a8\u09c7","image":{"@type":"ImageObject","inLanguage":"bn-BD","@id":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/bn\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/posts\/4060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/comments?post=4060"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/posts\/4060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/media\/11817"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/media?parent=4060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/categories?post=4060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/bn\/wp-json\/wp\/v2\/tags?post=4060"}],"curies":[{"name":"\u09a1\u09ac\u09cd\u09b2\u09bf\u0989\u09aa\u09bf","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}